Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Co-Diagnostics Inc (CODX)

Co-Diagnostics Inc (CODX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,551
  • Shares Outstanding, K 2,028
  • Annual Sales, $ 3,920 K
  • Annual Income, $ -37,640 K
  • EBIT $ -34 M
  • EBITDA $ -33 M
  • 60-Month Beta 1.25
  • Price/Sales 13.61
  • Price/Cash Flow N/A
  • Price/Book 0.31

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 123.64%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 921.55% on 10/22/25
  • IV Low 0.00% on 01/08/26
  • Expected Move (DTE 0) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 277
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 6,728
  • Open Int (30-Day) 9,817
  • Expected Range 5.53 to 5.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -3.90
  • Number of Estimates 1
  • High Estimate -3.90
  • Low Estimate -3.90
  • Prior Year -10.81
  • Growth Rate Est. (year over year) +63.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.84 +27.89%
on 01/02/26
11.10 -44.22%
on 12/10/25
-4.69 (-43.11%)
since 12/09/25
3-Month
4.84 +27.89%
on 01/02/26
46.50 -86.69%
on 10/27/25
-6.71 (-52.02%)
since 10/09/25
52-Week
4.84 +27.89%
on 01/02/26
46.50 -86.69%
on 10/27/25
-17.07 (-73.39%)
since 01/08/25

Most Recent Stories

More News
Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships

SALT LAKE CITY , Jan. 12, 2026 /PRNewswire/ --  Co-Diagnostics, Inc.  (Nasdaq: CODX)  ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the...

CODX : 6.19 (+1.14%)
Co-Diagnostics Announces Reverse Stock Split

SALT LAKE CITY , Dec. 30, 2025 /PRNewswire/ --  Co-Diagnostics, Inc. (Nasdaq: CODX)  ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the...

CODX : 6.19 (+1.14%)
Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies

The Australian patent represents the first patent granted for the Company's new point-of-care testing platform

CODX : 6.19 (+1.14%)
Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India

SALT LAKE CITY , Dec. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc.  (Nasdaq: CODX)  ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the...

CODX : 6.19 (+1.14%)
Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation

SALT LAKE CITY , Dec. 17, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development...

CODX : 6.19 (+1.14%)
Co-Diagnostics to Present on Co-Dxâ„¢ PCR Platform and AI Integration at Point-of-Care Testing 2025

SALT LAKE CITY , Dec. 9, 2025 /PRNewswire/ --  Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development...

CODX : 6.19 (+1.14%)
Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India

Ongoing Phase II preclinical study data for Co-Dx PCR MTB and HPV tests support advancement to clinical performance testing

CODX : 6.19 (+1.14%)
Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health

SALT LAKE CITY , Nov. 20, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development...

CODX : 6.19 (+1.14%)
Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dxâ„¢ PCR Platform to Support Submission to the U.S. FDA

SALT LAKE CITY , Nov. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development...

CODX : 6.19 (+1.14%)
Co-Diagnostics Reports Third Quarter 2025 Financial Results

SALT LAKE CITY , Nov. 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics," "Co-Dx," or "the Company") , a molecular diagnostics company with a unique, patented platform...

CODX : 6.19 (+1.14%)

Business Summary

Co-Diagnostics Inc. is a molecular diagnostics company. It develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company's technology is utilized for tests which are designed using the detection and/or analysis of nucleic acid molecules. It also uses proprietary technology...

See More

Key Turning Points

3rd Resistance Point 6.69
2nd Resistance Point 6.51
1st Resistance Point 6.35
Last Price 6.19
1st Support Level 6.01
2nd Support Level 5.83
3rd Support Level 5.67

See More

52-Week High 46.50
Fibonacci 61.8% 30.59
Fibonacci 50% 25.67
Fibonacci 38.2% 20.75
Last Price 6.19
52-Week Low 4.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar